4Q PREVIEW: Merck's experimental cancer drug is focus
This article was originally published in Scrip
Executive Summary
A promising cancer medicine in development has put Merck & Co in the spotlight after years of some miserable failures coming out of the drug maker’s once-storied research laboratories.